1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Injuries, Radiation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campana, B; Forrer, F; Lohri, A; Maecke, H; Mueller-Brand, J; Oechslin-Oberholzer, C | 1 |
| Mårtensson, L; Nilsson, R; Ohlsson, T; Sjögren, HO; Strand, SE; Tennvall, J | 1 |
1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Injuries, Radiation
| Article | Year |
|---|---|
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Rituximab; Treatment Outcome | 2012 |
1 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Injuries, Radiation
| Article | Year |
|---|---|
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
Topics: Adsorption; Animals; Antibodies, Monoclonal; Bone Marrow Diseases; Extracorporeal Circulation; Heterocyclic Compounds, 1-Ring; Immunoconjugates; Immunotoxins; Indium Radioisotopes; Neoplasm Transplantation; Neoplasms; Radiation Injuries; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Inbred BN; Transplantation, Isogeneic | 2007 |